Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega 3 FA Augmentation of Desvenlafaxine for MDD in Medically Ill Patients
NCT01803711Phase 3Terminated
- Sponsor
- UConn Health
- Start
- Feb 2013
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
A Phase 3 trial of omega-3 fatty acid in major depressive disorder (MDD), sponsored by UConn Health. Started Feb 2013; status: terminated.
02
Drugs
omega-3 fatty acid
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01803711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01803711.